Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | PARL | Q9H300 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31325586 | 0.87 | ALDH3A1 (0.49) | CHRM1DAOMEN1KMT2APOLB | |
| SCHEMBL29061702 | 0.80 | AURKA (0.40) | CHRM1DAOCXCL8NOD1SRC | |
| SCHEMBL6980480 | 0.80 | CMA1 (0.57) | CYP1A2CMA1ALDH1A1HPGDADORA3 | |
| SCHEMBL7462723 | 0.80 | HTR6 (0.49) | CXCL8NOD1SRCHTR6 | |
| SCHEMBL4434568 | 0.79 | DAO (0.52) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL6580197 | 0.76 | CYP1A2 (0.57) | CHRM1DAOMEN1KMT2APOLB | |
| SCHEMBL27635697 | 0.71 | MEN1 (0.44) | DAOMEN1KMT2APOLBCYP1A2 | |
| SCHEMBL7464976 | 0.70 | CMA1 (0.53) | CHRM1MEN1KMT2ASRCCMA1 | |
| SCHEMBL7464965 | 0.70 | CMA1 (0.85) | CHRM1MEN1KMT2ACMA1ALDH1A1 | |
| SCHEMBL12093313 | 0.70 | HTR6 (0.70) | MEN1KMT2ACXCL8NOD1SLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1598339-B1 | 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN | EURO CELTIQUE SA (LU) | 2009-06-24 | — | — | EP | disclosed |
| EP-0994890-B1 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-6455507-B1 | E.G., 2-BROMO-5,6-DICHLORO-1-BETA-D-RIBOPYRANOSYL-1H-BENZIMIDAZOLE; VIRICIDES, ESPECIALLY INFECTIONS OF HERPES AND CYTOMEGALO VIRUSES | SMITHKLINE BEECHAM CORPORATION | 2002-09-24 | — | — | US | disclosed |
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | GLAXO WELLCOME INC. | 2002-07-18 | — | — | US | disclosed |
| EP-0994890-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998056761-A2 | BENZIMIDAZOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1998-12-17 | — | — | WO | disclosed |
| US-5585394-A | INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| US-5585394-A | INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| US-5585394-A | INHIBITOR, ANTAGONIST OF VASOPRESSIN OR OXYTOCIN | SANOFI (FR) | 1996-12-17 | — | — | US | disclosed |
| CN-1106804-A | 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives | SANOFI SA (FR) | 1995-08-16 | — | — | CN | disclosed |
| CN-1106804-A | 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives | SANOFI SA (FR) | 1995-08-16 | — | — | CN | disclosed |
| CN-1106804-A | 1-Benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one derivatives | SANOFI SA (FR) | 1995-08-16 | — | — | CN | disclosed |
| EP-0636614-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0636614-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
| EP-0636614-A1 | Derivatives of 1-benzenesulfonyl-1,3-dihydro-2H-benzimidazol-2-one, their preparation and pharmaceutical compositions containing them | SANOFI (FR) | 1995-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020094963-A1 | BENZIMIDAZOLE DERIVATIVES | ZC3HAV1, BRPF3, BRD3 | CHRM1 4861/4885DAO 2261/4885MEN1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.